Írsko - angličtina - HPRA (Health Products Regulatory Authority)

lexon (uk) ltd - itraconazole - capsule - 100 milligram(s) - triazole derivatives; itraconazole

Kanada - angličtina - Health Canada

jamp pharma corporation - itraconazole - solution - 10mg - itraconazole 10mg - azoles

Singapur - angličtina - HSA (Health Sciences Authority)

goldplus universal pte ltd - itraconazole - solution - itraconazole 10 mg/ml

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ruxolitinib phosphate -

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - itraconazole - capsule, hard - 100 milligram(s) - triazole derivatives; itraconazole

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

janssen-cilag ltd - itraconazole - capsule, hard - 100 milligram(s) - triazole derivatives; itraconazole

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ruxolitinib phosphate 19.8mg equivalent to ruxolitinib 15 mg;   - tablet - 15 mg - active: ruxolitinib phosphate 19.8mg equivalent to ruxolitinib 15 mg   excipient: colloidal silicon dioxide hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium starch glycolate - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ruxolitinib phosphate 26.4mg equivalent to ruxolitinib 20 mg;   - tablet - 20 mg - active: ruxolitinib phosphate 26.4mg equivalent to ruxolitinib 20 mg   excipient: colloidal silicon dioxide hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium starch glycolate - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ruxolitinib phosphate 6.6mg equivalent to ruxolitinib 5 mg;   - tablet - 5 mg - active: ruxolitinib phosphate 6.6mg equivalent to ruxolitinib 5 mg   excipient: colloidal silicon dioxide hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium starch glycolate - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - apo-itraconazole indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.